The Cellular Morphology Core laboratory is constructed to meet the increasing demands of cell biology and transgene detection in the area of gene therapy research. Routine morphology support in the form of frozen, paraffin, and glycolmethacrylate sectioning for light level microscopy (LM) as well as standard transmission electron microscopy (EM) will be provided as a comprehensive service to investigators participating in SCOR projects. In addition, the core will emphasize state of the art methodologies for detecting transgene expression including in situ hybridization, immunocytochemistry, and histochemical detection of Beta-galactosidase and alkaline phosphatase reporter genes. The cellular morphology core will provide techniques of in situ hybridization and immunocytochemical detection of CFTR transgene as comprehensive services to preclinical studies of the Animal Models Core, the clinical studies of the Human Applications Laboratory (project III) and projects I and II. The cellular morphology core will interact with participating SCOR projects by two mechanisms: i) comprehensive service, and ii) facilities and technical support. Comprehensive services will be predominantly applied to clinical and preclinical projects. This will assure the minimal amount of technical variability and high quality assurance. Alternatively, the CMC will provide comprehensive services of in situ hybridization, immunocytochemistry, and histochemistry through the initial developmental stages of studies pertaining to projects I and II. Once methods for developmental studies have been defined within the core, the technologies will be transferred to individual investigators of projects I and II. During this phase of developmental projects, users will have full support for routine sectioning and full access to equipment and commonly used reagents for specialized techniques. Due to the specialized nature of electron microscopy, all EM services will be provided as a comprehensive service.

Project Start
Project End
Budget Start
1995-10-01
Budget End
1996-09-30
Support Year
3
Fiscal Year
1996
Total Cost
Indirect Cost
Name
University of Pennsylvania
Department
Type
DUNS #
042250712
City
Philadelphia
State
PA
Country
United States
Zip Code
19104
Bals, R; Weiner, D J; Meegalla, R L et al. (2001) Salt-independent abnormality of antimicrobial activity in cystic fibrosis airway surface fluid. Am J Respir Cell Mol Biol 25:21-5
Gao, G P; Engdahl, R K; Wilson, J M (2000) A cell line for high-yield production of E1-deleted adenovirus vectors without the emergence of replication-competent virus. Hum Gene Ther 11:213-9
Chirmule, N; Propert, K; Magosin, S et al. (1999) Immune responses to adenovirus and adeno-associated virus in humans. Gene Ther 6:1574-83
Zuckerman, J B; Robinson, C B; McCoy, K S et al. (1999) A phase I study of adenovirus-mediated transfer of the human cystic fibrosis transmembrane conductance regulator gene to a lung segment of individuals with cystic fibrosis. Hum Gene Ther 10:2973-85
Bals, R; Weiner, D J; Moscioni, A D et al. (1999) Augmentation of innate host defense by expression of a cathelicidin antimicrobial peptide. Infect Immun 67:6084-9
Chirmule, N; Truneh, A; Haecker, S E et al. (1999) Repeated administration of adenoviral vectors in lungs of human CD4 transgenic mice treated with a nondepleting CD4 antibody. J Immunol 163:448-55
Chirmule, N; Hughes, J V; Gao, G P et al. (1998) Role of E4 in eliciting CD4 T-cell and B-cell responses to adenovirus vectors delivered to murine and nonhuman primate lungs. J Virol 72:6138-45
Jiang, Q; Mak, D; Devidas, S et al. (1998) Cystic fibrosis transmembrane conductance regulator-associated ATP release is controlled by a chloride sensor. J Cell Biol 143:645-57
Jooss, K; Turka, L A; Wilson, J M (1998) Blunting of immune responses to adenoviral vectors in mouse liver and lung with CTLA4Ig. Gene Ther 5:309-19
Goldman, M J; Lee, P S; Yang, J S et al. (1997) Lentiviral vectors for gene therapy of cystic fibrosis. Hum Gene Ther 8:2261-8

Showing the most recent 10 out of 12 publications